[go: up one dir, main page]

MX2007007919A - Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp). - Google Patents

Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).

Info

Publication number
MX2007007919A
MX2007007919A MX2007007919A MX2007007919A MX2007007919A MX 2007007919 A MX2007007919 A MX 2007007919A MX 2007007919 A MX2007007919 A MX 2007007919A MX 2007007919 A MX2007007919 A MX 2007007919A MX 2007007919 A MX2007007919 A MX 2007007919A
Authority
MX
Mexico
Prior art keywords
cetp inhibitors
benzylamine derivatives
novel benzylamine
benzylamine compounds
novel
Prior art date
Application number
MX2007007919A
Other languages
English (en)
Inventor
Christopher W Alexander
Ish Kumar Khanna
Sivaram Pillarisetti
Anima Baruah
Dibyendu De
Santanu Maitra
Jennepalli Sreenu
Indu Dager
Original Assignee
Reddy Us Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reddy Us Therapeutics Inc filed Critical Reddy Us Therapeutics Inc
Publication of MX2007007919A publication Critical patent/MX2007007919A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Quinoline Compounds (AREA)
  • Lubricants (AREA)

Abstract

La presente invencion proporciona, entre otras cosas, nuevos compuestos de bencilaminas, composiciones que comprenden compuestos de bencilaminas, metodos para elaborar compuestos de bencilaminas, y metodos para usar compuestos de bencilaminas para tratar o prevenir una variedad de condiciones o enfermedades asociadas con metabolismo de lipoproteinas.
MX2007007919A 2004-12-31 2005-12-28 Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp). MX2007007919A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64079804P 2004-12-31 2004-12-31
PCT/US2005/047203 WO2006073973A2 (en) 2004-12-31 2005-12-28 Novel benzylamine derivatives as cetp inhibitors

Publications (1)

Publication Number Publication Date
MX2007007919A true MX2007007919A (es) 2008-01-22

Family

ID=36648035

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007007919A MX2007007919A (es) 2004-12-31 2005-12-28 Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).

Country Status (10)

Country Link
US (2) US9040558B2 (es)
EP (1) EP1848430B1 (es)
JP (1) JP5096927B2 (es)
KR (1) KR101238525B1 (es)
CN (2) CN103102303B (es)
CA (1) CA2605214C (es)
DK (1) DK1848430T3 (es)
ES (2) ES2644450T3 (es)
MX (1) MX2007007919A (es)
WO (1) WO2006073973A2 (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
AU2006330072B2 (en) * 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
JP2009522224A (ja) * 2005-12-29 2009-06-11 ノバルティス アクチエンゲゼルシャフト コレステリルエステル輸送タンパク質（ｃｅｔｐ）の阻害剤としてのピリジニルアミン誘導体
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
US8383660B2 (en) * 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
GB0609268D0 (en) * 2006-05-10 2006-06-21 Novartis Ag Organic compounds
EP2024356A1 (en) * 2006-05-10 2009-02-18 Novartis AG Bicyclic derivatives as cetp inhibitors
CN101443324A (zh) * 2006-05-11 2009-05-27 诺瓦提斯公司 作为cetp抑制剂的苄胺衍生物
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
JP2010509388A (ja) * 2006-11-15 2010-03-25 ノバルティス アーゲー 有機化合物
KR20090080523A (ko) * 2006-11-15 2009-07-24 노파르티스 아게 Ｃετρ 억제제로서의 헤테로시클릭 유도체
WO2008097976A1 (en) * 2007-02-09 2008-08-14 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
WO2008115442A1 (en) 2007-03-16 2008-09-25 Concert Pharmceuticals, Inc. Inhibitors of cholesterol ester transfer protein
PT2149563E (pt) * 2007-04-13 2015-02-18 Kowa Co Novo composto de pirimidina que apresenta uma estrutura de dibenzilamina, e um medicamento que contém esse composto
WO2008137105A1 (en) * 2007-05-07 2008-11-13 Merck & Co., Inc. Method of treatment using fused aromatic compounds having anti-diabetic activity
JP4846769B2 (ja) * 2007-07-30 2011-12-28 田辺三菱製薬株式会社 医薬組成物
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007063671A1 (de) 2007-11-13 2009-06-25 Sanofi-Aventis Deutschland Gmbh Neue kristalline Diphenylazetidinonhydrate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
ES2598358T3 (es) * 2009-02-13 2017-01-27 Ucb Pharma, S.A. Derivados de quinolina como inhibidores de PI3K quinasa
KR20120060207A (ko) 2009-08-26 2012-06-11 사노피 신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
JP5964965B2 (ja) * 2011-08-18 2016-08-03 ドクター レディズ ラボラトリーズ リミテッド コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物
CN103958511A (zh) * 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
US20140303198A1 (en) 2011-11-29 2014-10-09 Kowa Company, Ltd. Agent for inhibiting expression of npc1l1 and/or lipg mrna and agent for preventing and/or treating obesity
WO2014017569A1 (ja) * 2012-07-26 2014-01-30 興和株式会社 血中ｌｄｌを低下させるための医薬
WO2014076568A2 (en) * 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
JP2015054838A (ja) * 2013-09-12 2015-03-23 興和株式会社 血中ｌｄｌコレステロールを低下させる医薬
US10214502B2 (en) * 2016-10-04 2019-02-26 Mayo Foundation For Medical Education And Research Method of inhibiting apolipoprotein-E expression while increasing expression of at least one of LDL-receptor protein or AbcA1 protein comprising administering a small compound
CN108329330B (zh) * 2017-01-20 2021-05-04 复旦大学 2-苄氧苯基噁唑并吡啶类化合物及其药物用途

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965643A (en) 1960-12-20 Derivatives of pyrazolo
CH273953A (de) * 1948-05-21 1951-03-15 Ciba Geigy Verfahren zur Herstellung von Aminen.
US2858309A (en) 1956-05-07 1958-10-28 Ciba Pharm Prod Inc New aminobenzene sulfonamide
US3546295A (en) 1968-08-01 1970-12-08 Exxon Research Engineering Co N-cycloalkyl anilines
US3713499A (en) * 1971-08-11 1973-01-30 Gulf Research Development Co Method and apparatus for treating drilling mud
GB2087390B (en) * 1980-10-29 1984-06-13 Nippon Kayaku Kk 5,6,7,8-tetrahydro-1,6-naphthyridine derivatives and their preparation
JPH01104052A (ja) 1987-06-12 1989-04-21 Yoshitomi Pharmaceut Ind Ltd ピリジン誘導体
ATE92752T1 (de) 1987-07-08 1993-08-15 American Home Prod Spruehgetrocknete ibuprofen-zusammensetzungen.
US5089073A (en) * 1988-09-26 1992-02-18 W. R. Grace & Co.-Conn. High strength laminated film for chub packaging
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
GB8912784D0 (en) 1989-06-02 1989-07-19 Wyeth John & Brother Ltd Amines
AU641394B2 (en) 1989-06-02 1993-09-23 John Wyeth & Brother Limited Amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
US5260301A (en) * 1990-03-01 1993-11-09 Fujisawa Pharmaceutical Co., Ltd. Pharmaceutical solution containing FK-506
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
ZA924659B (en) 1991-06-25 1993-03-31 Merck & Co Inc New substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
TW225469B (es) 1991-11-12 1994-06-21 Nissan Kagakl Kogyo
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
EP0585913B1 (en) * 1992-09-04 1997-12-29 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
EP0585500A1 (en) 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
WO1994013636A1 (en) 1992-12-17 1994-06-23 Merck & Co., Inc. New substituted azetidinones as anti-inflammatory and antidegenerative agents
MY131441A (en) 1992-12-29 2007-08-30 American Cyanamid Co Amidrazones and their use as insecticidal and acaricidal agents
EP0713483B1 (en) 1993-08-12 2003-01-15 AstraZeneca AB Amidine derivatives with nitric oxide synthetase activities
US5491152A (en) 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
IT1270615B (it) * 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JPH0892224A (ja) 1994-09-16 1996-04-09 Kumiai Chem Ind Co Ltd ３，５−置換フェニルトリアゾール誘導体および殺虫、殺ダニ剤
JPH0892225A (ja) 1994-09-29 1996-04-09 Nissan Chem Ind Ltd トリアゾールグリコール酸アミド誘導体
CA2206315A1 (en) 1994-11-29 1996-06-06 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
JPH09235276A (ja) * 1995-12-27 1997-09-09 Takeda Chem Ind Ltd オキサゾール誘導体、その製造法および用途
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
NZ330739A (en) 1996-05-20 1999-06-29 Janssen Pharmaceutica Nv Particulate solid dispersion of itraconazole and a water soluble polymer
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
AU4607497A (en) * 1996-10-02 1998-05-11 Trustees Of Boston University Synthesis of aromatic compounds by diels-alder reaction on solid support
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
WO1998057925A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 2-[(aminothioxomethyl)-hydrazono]-2-arylethyl carbamates
US6008362A (en) 1997-06-16 1999-12-28 Commons; Thomas Joseph Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
WO1998057927A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
WO1998057928A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
US5977170A (en) 1997-06-16 1999-11-02 American Home Products Corporation Elevation of HDL cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
CN1303378A (zh) * 1998-04-27 2001-07-11 国家科研中心 3－(氨基－或氨基烷基)吡啶酮衍生物和它们在hiv相关疾病治疗中的用途
US6121271A (en) 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE19845202A1 (de) 1998-10-01 2000-04-06 Wella Ag Haarwuchsmittel
PL348193A1 (en) 1998-12-11 2002-05-06 Pharmasolutions Self-emulsifying compositions for drugs poorly soluble in water
EP1027885B1 (en) 1999-02-09 2008-07-09 Pfizer Products Inc. Basic drug compositions with enhanced bioavailability
BR0008489A (pt) 1999-02-24 2002-02-05 Hoffmann La Roche Derivados de fenil- e piridinila
PL202732B1 (pl) 1999-06-23 2009-07-31 Syngenta Participations Ag Sposób wytwarzania tiametoksamu
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6451823B1 (en) 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
EP1108426A3 (en) 1999-12-02 2002-10-02 Pfizer Products Inc. Use of prostaglandin agonists to treat erectile dysfunction or impotence
US7078057B2 (en) 1999-12-20 2006-07-18 Kerkhof Nicholas J Process for producing nanometer particles by fluid bed spray-drying
DE19962300A1 (de) 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
WO2001060458A2 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
WO2001060369A1 (en) 2000-02-18 2001-08-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US20020019527A1 (en) * 2000-04-27 2002-02-14 Wei-Bo Wang Substituted phenyl farnesyltransferase inhibitors
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
CA2415643C (en) 2000-07-17 2010-11-16 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical composition for oral use with improved absorption
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
CA2420967A1 (en) * 2000-08-07 2002-02-14 Neurogen Corporation Heterocyclic compounds as ligands of the gabaa receptor
JP2002145778A (ja) * 2000-08-29 2002-05-22 Takeda Chem Ind Ltd Ｇｒｋ阻害剤
US6576644B2 (en) * 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU2001294557A1 (en) 2000-09-11 2002-03-26 Merck And Co., Inc. Thrombin inhibitors
EP1318995B1 (en) * 2000-09-19 2006-03-08 Centre National De La Recherche Scientifique (Cnrs) Pyridinone and pyridinethione derivatives having hiv inhibiting properties
WO2002042273A2 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
WO2002055484A1 (en) * 2001-01-12 2002-07-18 Takeda Chemical Industries, Ltd. Biaryl compound, process for producing the same, and agent
SI1379525T1 (sl) 2001-02-21 2007-12-31 Astrazeneca Ab Heteropoliciklične spojine in njihova uporaba kot antagonisti metabotropnih glutamatnih receptorjev
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7459470B2 (en) 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
IL158765A0 (en) 2001-06-21 2004-05-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
CA2448864C (en) 2001-06-22 2008-04-22 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
JP2004534811A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク ポリマーと薬剤の集合体を含む医薬組成物
WO2003000238A1 (en) 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
JP2003221376A (ja) * 2001-11-21 2003-08-05 Japan Tobacco Inc Ｃｅｔｐ活性阻害剤
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
BR0308721A (pt) * 2002-03-29 2007-01-09 Neurogen Corp composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica acondicionada, e, métodos para inibir a atividade transdutora de sinal de um receptor de c5a celular, a ligação de c5a ao receptor de c5a, e quimiotaxia celular modulada por receptor de c5a, para tratar um paciente, e para localizar receptores de c5a em uma amostra de tecido
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
EP1829858A3 (en) 2002-08-30 2007-10-03 Japan Tobacco, Inc. Dibenzylamine compounds and pharmaceutical use thereof
EP1578415B1 (en) 2002-12-20 2008-09-10 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
GB0303683D0 (en) 2003-02-18 2003-03-19 Prolysis Ltd Antimicrobial agents
CA2516627A1 (en) 2003-02-28 2004-09-16 Bayer Pharmaceuticals Corporation Substituted pyridine derivatives useful in the treatment of cancer and other disorders
KR20050105511A (ko) 2003-03-04 2005-11-04 화이자 프로덕츠 인크. 의학적 치료에서 ｅｐ2 선택적 수용체 효능제의 용도
ES2298782T3 (es) 2003-06-11 2008-05-16 Eli Lilly And Company 3-aminopirrolidinas como inhibidores de la reabsorcion de monoaminas.
BRPI0413363A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc formas de dosagem fornecendo liberação controlada de inibidores de proteìna de transferência de ésteres de colesterila e liberação imediata de inibidores de hmg-coa redutase
CA2536461A1 (en) 2003-08-27 2005-03-10 Janssen Pharmaceutica, N.V. Aryl piperidine amides
CN1886124A (zh) 2003-09-26 2006-12-27 日本烟草产业株式会社 抑制残余脂蛋白产生的方法
WO2005058037A1 (en) * 2003-12-12 2005-06-30 Syngenta Participations Ag Picolinylpyrazoles as herbicides
WO2005058831A1 (en) * 2003-12-12 2005-06-30 Syngenta Participations Ag Novel herbicides
ATE402180T1 (de) 2004-03-26 2008-08-15 Lilly Co Eli Verbindungen zur behandlung von dyslipidemie
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
US7737295B2 (en) 2004-04-13 2010-06-15 Merck Sharp & Dohme Corp. CETP inhibitors
AR053784A1 (es) 2004-11-23 2007-05-23 Pfizer Prod Inc Compuestos y derivados tetrazolicos de dibencil amina. composiciones farmaceuticas.
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US8828438B2 (en) 2005-05-31 2014-09-09 Bend Research, Inc. Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors and HMG-CoA reductase
AU2006330072B2 (en) 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
US8030359B2 (en) 2006-02-09 2011-10-04 Merck Sharp & Dohme Corp. Polymer formulations of CETP inhibitors
EP2024356A1 (en) 2006-05-10 2009-02-18 Novartis AG Bicyclic derivatives as cetp inhibitors
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors

Also Published As

Publication number Publication date
US20150216866A1 (en) 2015-08-06
US9040558B2 (en) 2015-05-26
DK1848430T3 (da) 2017-11-06
WO2006073973A3 (en) 2008-12-04
ES2644450T3 (es) 2017-11-29
US20060178514A1 (en) 2006-08-10
CA2605214C (en) 2016-07-12
ES2615340T3 (es) 2017-06-06
CA2605214A1 (en) 2006-07-13
KR20070102696A (ko) 2007-10-19
KR101238525B1 (ko) 2013-02-28
JP5096927B2 (ja) 2012-12-12
EP1848430A4 (en) 2011-12-28
JP2008528447A (ja) 2008-07-31
EP1848430B1 (en) 2017-08-02
HK1131055A1 (en) 2010-01-15
CN101443006B (zh) 2012-10-10
EP1848430A2 (en) 2007-10-31
CN103102303A (zh) 2013-05-15
WO2006073973A2 (en) 2006-07-13
CN101443006A (zh) 2009-05-27
CN103102303B (zh) 2015-10-28
US9782407B2 (en) 2017-10-10

Similar Documents

Publication Publication Date Title
MX2007007919A (es) Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
TW200714283A (en) Method and composition for treating peripheral vascular diseases
PL1836169T3 (pl) Kompozycje i sposoby leczenia zaburzeń związanych z proliferacją komórek
TW200640924A (en) VEGF-R2 inhibitors and methods
TW200619218A (en) Pyrimidines as PLK inhibitors
IL195256A0 (en) Compositions of r(+)and s(-)pramipexole and methods of using the same
GEP20084551B (en) 4-phenylamino-quinazolin-6-yl-amides
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
IL183514A0 (en) Pyrrolidine inhibitors of iap
TW200626601A (en) Novel compounds
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
WO2007106192A3 (en) Inhibitors of iap
MXPA05012061A (es) Preparacion y uso de derivados alquilarilo para el tratamiento de la obesidad.
TW200612892A (en) Novel compounds
MY142988A (en) Novel aminobenzophenone compounds
UA83875C2 (ru) Производные хинолина для применения в качестве микобактериальных ингибиторов
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
TW200624426A (en) BACE inhibitors
TW200736229A (en) Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
MX2010002938A (es) Derivados de (3-hidroxi-4-amino-butan-2-il)-3-(2-tiazol-2-il-pirro lidin-1-carbonil)benzamida y compuestos relacionados como inhibidores de beta-secretasa para tratar enfermedad de alzheimer.
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
MX2010007543A (es) Inhibidores de iap.
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof

Legal Events

Date Code Title Description
FG Grant or registration